Literature DB >> 35044894

Body Mass Index Recovery after Lung Transplant for Cystic Fibrosis.

Joseph B Pryor1, Miranda C Bradford2, Ann L Jennerich3, Travis Y Hee Wai3, Joseph M Pilewski4, Siddhartha G Kapnadak3, Moira L Aitken3, Christopher H Goss3,5, Kathleen J Ramos3.   

Abstract

Rationale: Many lung transplant recipients with cystic fibrosis (CF) have low preoperative body mass index (BMI); however, post-transplant BMI recovery is not well understood.
Objectives: To evaluate BMI recovery (⩾18.5 kg/m2) among CF lung transplant recipients with low preoperative BMI and to investigate the association of survival with BMI recovery.
Methods: The United Network for Organ Sharing and CF Foundation patient registries (June 2005-December 2016) were used to identify CF lung transplant recipients. Among recipients surviving ⩾1 year, Cox modeling compared post-transplant 1-year conditional survival between recipients with low (<17 and 17-18.49 kg/m2) versus normal preoperative BMI, stratified by BMI recovery.
Results: Of 1,977 CF lung transplant recipients, 272 (14%) and 449 (23%) had a preoperative BMI of <17 and 17-18.49 kg/m2, respectively. For subgroups with a BMI of <17 and 17-18.49 kg/m2, 29% versus 49%, respectively, of those alive at 1 year recovered their BMI. Among recipients with low preoperative BMI, adjusted post-transplant 1-year conditional survival was worse than that in those with preoperative BMI ⩾ 18.5 kg/m2; however, BMI recovery mitigated this. Preoperative BMI < 17 kg/m2 had an adjusted hazard ratio of 1.29 (95% confidence interval [CI], 0.92-1.81) with BMI recovery versus 1.57 (95% CI, 1.09-2.25) without recovery, and preoperative BMI 17-18.49 kg/m2 had an adjusted hazard ratio of 1.28 (95% CI, 1.02-1.61) with BMI recovery versus 1.72 (95% CI, 1.14-2.59) without recovery. Conclusions: Patients with lower preoperative BMI were less likely to achieve BMI recovery within 1 year. However, for those who did, BMI recovery within 1 year after transplant was associated with longer survival.

Entities:  

Keywords:  BMI; forced expiratory volume in 1 second; lung function; survival; underweight

Mesh:

Year:  2022        PMID: 35044894      PMCID: PMC9278631          DOI: 10.1513/AnnalsATS.202108-969OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  31 in total

1.  Relative underweight in cystic fibrosis and its prognostic value.

Authors:  R Kraemer; A Rüdeberg; B Hadorn; E Rossi
Journal:  Acta Paediatr Scand       Date:  1978-01

Review 2.  Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.

Authors:  Malena Cohen-Cymberknoh; David Shoseyov; Eitan Kerem
Journal:  Am J Respir Crit Care Med       Date:  2011-02-17       Impact factor: 21.405

3.  Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States.

Authors:  Kathleen J Ramos; Bradley S Quon; Sonya L Heltshe; Nicole Mayer-Hamblett; Erika D Lease; Moira L Aitken; Noel S Weiss; Christopher H Goss
Journal:  Chest       Date:  2017-01-20       Impact factor: 9.410

4.  Discordant utility of ideal body weight and body mass index as predictors of mortality in lung transplant recipients.

Authors:  Daniel A Culver; Peter J Mazzone; Farah Khandwala; Holli C Blazey; Malcolm M Decamp; Jeffrey T Chapman
Journal:  J Heart Lung Transplant       Date:  2005-02       Impact factor: 10.247

5.  Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.

Authors:  G Steinkamp; B Wiedemann
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

6.  Baseline lung allograft dysfunction is associated with impaired survival after double-lung transplantation.

Authors:  Jonathan Liu; Kathy Jackson; Justin Weinkauf; Ali Kapasi; Alim Hirji; Steve Meyer; John Mullen; Jayan Nagendran; Dale Lien; Kieran Halloran
Journal:  J Heart Lung Transplant       Date:  2018-02-27       Impact factor: 10.247

7.  Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation: A United Network for Organ Sharing Registry Study.

Authors:  Kathleen J Ramos; Siddhartha G Kapnadak; Miranda C Bradford; Ranjani Somayaji; Eric D Morrell; Joseph M Pilewski; Erika D Lease; Michael S Mulligan; Moira L Aitken; Cynthia J Gries; Christopher H Goss
Journal:  Chest       Date:  2020-01-17       Impact factor: 9.410

8.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Authors:  Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy
Journal:  Lancet       Date:  2019-10-31       Impact factor: 79.321

9.  Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States.

Authors:  Christopher H Goss; Jenna Sykes; Sanja Stanojevic; Bruce Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Bradley S Quon; Anne L Stephenson
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 30.528

10.  Body Mass Index Recovery after Lung Transplant for Cystic Fibrosis.

Authors:  Joseph B Pryor; Miranda C Bradford; Ann L Jennerich; Travis Y Hee Wai; Joseph M Pilewski; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos
Journal:  Ann Am Thorac Soc       Date:  2022-07
View more
  1 in total

1.  Body Mass Index Recovery after Lung Transplant for Cystic Fibrosis.

Authors:  Joseph B Pryor; Miranda C Bradford; Ann L Jennerich; Travis Y Hee Wai; Joseph M Pilewski; Siddhartha G Kapnadak; Moira L Aitken; Christopher H Goss; Kathleen J Ramos
Journal:  Ann Am Thorac Soc       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.